# IMRN catalysts: Immuron Ltd PDUFA dates and FDA events

Canonical: https://sec-api.dev/companies/imrn/catalysts

> Immuron Ltd (IMRN) has no upcoming catalysts in this calendar. The latest recorded is the Immuron Ltd FDA approval, Mar 2026.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only, exact day, half-year only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Company

| Field | Value |
| --- | --- |
| Name | Immuron Ltd |
| Ticker | IMRN (Nasdaq) |
| SEC CIK | 1660046 |
| SIC | 2834 |
| SEC filings | https://sec-api.dev/companies/imrn |

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| Apr 2023 | [SER-109 FDA approval](https://sec-api.dev/pdufa/ser-109) | IMRN |  | completed, approved | "(Business Wire) Phase 3 Became FDA approved Apr 2023; subsequently commercialized and later moved into the 2024 asset sale to Nestlé (row above)." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1660046/000121390026113101/ea030992701ex99-1.htm)) |
| Oct 2025 | [Travelan (colostrum) topline data readout](https://sec-api.dev/pdufa/colostrum) | IMRN |  | scheduled | "Immuron reported on May 30 that we anticipated the final visit of the Last Patient for the Uniformed Services University Travelan® field study would be in July 2025 with topline results to follow in October 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1660046/000121390025094905/ea025986101ex99-1_immuron.htm)) |
| November 5, 2025 | [IMM-529 FDA approval](https://sec-api.dev/pdufa/imm-529) | IMRN |  | completed, approved | "2025: Immuron Limited (ASX: IMC; NASDAQ: IMRN), is pleased to announce that the United States Food and Drug Administration (FDA) has approved" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1660046/000121390025106425/ea026414101ex99-1_immuron.htm)) |
| 1H 2026 | [IMM-529 trial start](https://sec-api.dev/pdufa/imm-529) | IMRN | Clostridioides difficile infection | scheduled | "The Company plans to initiate a Phase 2 clinical trial for IMM-529 in individuals with Clostridioides difficile infection (CDI) during the first half of 2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1660046/000121390025106425/ea026414101ex99-1_immuron.htm)) |
| Mar 2026 | [Immuron Ltd FDA approval](https://sec-api.dev/companies/imrn/catalysts) | IMRN |  | completed, approved | "8 IMM - 529 Deal Potential Status update (as of March 2026) Stage at deal Financial terms (public) Licensed Asset Licensee / Acquirer Licensor / Asset Owner Year FDA approved (Apr 2023) and commercialized by Nestlé Health Science" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1660046/000121390026053527/ea028979701ex99-1.htm)) |

## Drugs

- [Travelan (colostrum)](https://sec-api.dev/pdufa/colostrum): 
- [IMM-529](https://sec-api.dev/pdufa/imm-529): clostridioides difficile infection

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/companies/imrn/catalysts.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "IMRN catalysts: Immuron Ltd PDUFA dates and FDA events." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/companies/imrn/catalysts

```bibtex
@misc{secapidev_companies_imrn_catalysts_20261116,
  title        = {IMRN catalysts: Immuron Ltd PDUFA dates and FDA events},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/companies/imrn/catalysts}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_companies_imrn_catalysts_20261116","title":"IMRN catalysts: Immuron Ltd PDUFA dates and FDA events","publisher":"sec-api.dev","URL":"https://sec-api.dev/companies/imrn/catalysts","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
